Ozempic, Inhalers, In The Crosshairs As FTC Goes After Hundreds More ‘Junk Patents’

Teva, GSK, Boehringer, And Novartis Among Companies Targeted In Fresh Wave

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

The US Federal Trade Commission is not resting on its laurels after seeing some success in its initial challenge to what it deems improper or irrelevant US patents that may be strangling cheaper generic competition.

Federal Trade Commission seal sign logo FTC
• Source: Andriy Blokhin / Alamy Stock Photo

Novo Nordisk’s Ozempic (semaglutide) is among 20 costly innovator drugs – and a contributing factor in more than 300 US patents – that are being targeted by the US Federal Trade Commission’s latest campaign against improperly-listed ‘junk’ patents, which the US watchdog says “can delay cheaper generic alternatives from entering the market, keeping brand name drug prices artificially high.”

As well as the landmark GLP-1 receptor agonist, the FTC has also taken aim at a number of leading asthma...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

ADHD

This is regarding ADHD.

GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

 
• By Nabil

In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

MPP Finds Three More Partners On Key Hepatitis C Treatment

 
• By Akriti Seth

The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

 
• By David Wallace

Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.